查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018403

遺傳性血管性水腫治療市場規模、佔有率和趨勢分析報告：按治療方法、應用、地區和細分市場預測（2026-2033 年）

Hereditary Angioedema Therapeutics Market Size, Share & Trends Analysis Report By Treatment (C1-Inhibitor Concentrates, Bradykinin B2 Receptor Antagonist), By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

遺傳性血管性水腫治療市場概述

2025 年全球遺傳性血管性水腫治療市場規模估計為 36 億美元，預計到 2033 年將達到 81.8 億美元，2026 年至 2033 年的複合年成長率為 10.43%。

由於診斷率的提高和臨床對罕見遺傳疾病認知的增強，遺傳性血管性水腫治療的全球市場正在擴大。

專業檢測手段的普及使得患者能夠更早被發現，以便及時啟動治療。針對疾病潛在機制的標靶治療的出現，提高了治療效果和患者的信心。製藥領域的創新帶來了便捷的給藥途徑，例如皮下注射和口服製劑，從而提高了遵守用藥。已開發國家和新興國家不斷上升的盛行率報告，持續推高了對有效治療方法的需求。

生物製藥和新型藥物的進步是推動市場成長要素。長效預防性療法因其能降低癲癇發作頻率並改善患者生活品質，正日益受到醫生的青睞。正在研發中的口服激肽釋放酶抑制劑和基因標靶治療正在拓展未來的治療選擇。積極的臨床試驗和監管核准正在加速創新治療方法的上市。例如，HCPLive預計將於2025年12月獲得美國食品藥物管理局（FDA）的批准，隨後galadasimab GXII將於6月獲批，Andembry將於7月獲批，sevetraalstat（Ekterly）將於7月獲批，donidalorsen（Dawnzera）將於8月獲批。該疾病影響全球約五萬分之一的人口，在美國約有6000名患者。在這些核准之前，已有九種治療方法可供使用，但預計到2026年，這一數字將增加到十二種，這反映了口服和注射劑型選擇的擴展。生技公司與大型製藥公司之間的策略夥伴關係進一步加強了研發能力和全球分銷網路。

醫療基礎設施的改善和專科醫療網路的擴展進一步促進了市場成長。免疫學家和罕見疾病專家的更多參與提高了疾病管理標準和治療方案的可及性。患者支持活動和教育計畫正在促進患者接受治療並堅持長期治療。一些地區優惠的保險報銷方案提高了患者獲得高成本生物製藥的機會。例如，2025年12月，《罕見疾病顧問》（Rare Disease Advisor）報告稱，美國食品藥物管理局（FDA）核准了velotralstat（商品名為ORLADEYO）作為首個用於2至11歲兒童遺傳性血管性水腫的口服血漿激肽釋放酶抑製劑預防性治療藥物。此次核准將現有核准範圍擴大至12歲及以上患者。此兒童適應症的核准是基於APeX P試驗，該試驗納入了29名2至11歲的患者（48.3%為女性）。平均年齡為8歲，平均發病年齡為2歲。研究顯示，每月癲癇發作頻率持續下降，血中濃度達高峰時間中位數為3.9小時（範圍0.9-6.0小時）。對罕見疾病研究投入的持續增加，將持續支持創新和市場競爭成長。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：遺傳性血管性水腫治療市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：遺傳性血管性水腫治療市場：依療法分類的商業分析

  • 按治療方法分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按治療方法分類，2021-2033 年
  • C1抑制劑濃縮物
  • 緩激肽B2受體拮抗劑
  • 激肽釋放酶抑制劑
  • 其他

第5章：遺傳性血管性水腫治療市場：依最終用途分類的業務分析

  • 按最終用途分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測和趨勢分析：按最終用途分類，2021-2033 年
  • 預防
  • 一經請求

第6章：遺傳性血管性水腫治療市場：依給藥途徑分類的業務分析

  • 按行政途徑分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按給藥途徑分類，2021-2033 年
  • 靜脈
  • 皮下
  • 口服

第7章：遺傳性血管性水腫治療市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第8章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • BioCryst Pharmaceuticals, Inc.
    • Ionis Pharmaceuticals
    • CSL
    • Attune Pharmaceuticals
    • Adverum Biotechnologies, Inc.
    • KalVista Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
    • Pharming
    • Sanofi
    • Pharvaris BV
    • Arrowhead Pharmaceuticals, Inc.
Product Code: GVR-3-68038-156-6

Hereditary Angioedema Therapeutics Market Summary

The global hereditary angioedema therapeutics market size was estimated at USD 3.60 billion in 2025 and is projected to reach USD 8.18 billion by 2033, growing at a CAGR of 10.43% from 2026 to 2033. The global hereditary angioedema therapeutics market is expanding due to increasing diagnosis rates and greater clinical awareness of rare genetic disorders.

Improved access to specialized testing has enabled earlier identification of patients, which supports timely treatment initiation. The availability of targeted therapies that address underlying disease pathways has strengthened treatment outcomes and patient confidence. Pharmaceutical innovation has introduced convenient administration options, including subcutaneous and oral formulations, which improve adherence. Rising prevalence reporting across developed and emerging regions continues to create sustained demand for effective therapies.

Advancements in biologics and novel drug classes represent another major growth driver for the market. Long-acting prophylactic therapies have reduced attack frequency and improved quality of life for patients, which has increased adoption among physicians. Oral kallikrein inhibitors and gene-targeted approaches under development are expanding the future treatment landscape. Strong clinical trial activity and regulatory approvals have accelerated commercialization timelines for innovative therapies. For instance, December 2025, HCPLive reported that the U.S. Food and Drug Administration had approved three new hereditary angioedema treatments in 2025 over three months, including garadacimab gxii, Andembry, in June, sebetralstat, Ekterly, in July, and donidalorsen, Dawnzera, in August, in a disease affecting about 1 in 50,000 people globally and nearly 6,000 in the United States. Prior to these approvals, 9 therapies were available, increasing to 12 by 2026, reflecting the expansion of oral and injectable options. Strategic collaborations between biotechnology firms and larger pharmaceutical companies have further enhanced research capabilities and global distribution reach.

Healthcare infrastructure improvements and the expansion of specialty care networks are further contributing to market growth. Increased involvement of immunologists and rare disease specialists has strengthened disease management standards and treatment utilization. Patient advocacy initiatives and education programs have encouraged treatment uptake and long-term therapy compliance. Favorable reimbursement coverage in several regions has improved patient access to high-cost biologic treatments. For instance, in December 2025, Rare Disease Advisor reported that the U.S. Food and Drug Administration had approved berotralstat, marketed as ORLADEYO, as the first oral plasma kallikrein inhibitor prophylactic therapy for hereditary angioedema in children aged 2 to 11 years, extending prior approval for patients 12 years and older. The pediatric approval was based on the APeX P trial involving 29 patients aged 2 to 11 years, 48.3 percent female, with a mean age of 8 years and a mean onset at 2 years, demonstrating sustained reductions in monthly attack rates and a peak median concentration of 3.9 hours, range 0.9 to 6.0 hours. Growing investment in rare disease research continues to support innovation and competitive market expansion.

Global Hereditary Angioedema Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hereditary angioedema therapeutics market based on treatment, end use, route of administration, and region:

  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • C1-Inhibitor Concentrates
  • Bradykinin B2 Receptor Antagonist
  • Kallikrein Inhibitor
  • Others
  • End use Outlook (Revenue, USD Million, 2021 - 2033)
  • Prophylaxis
  • On-demand
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Intravenous
  • Subcutaneous
  • Oral
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End Use
    • 1.2.3. Route of Administration
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Hereditary Angioedema Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Hereditary Angioedema Therapeutics Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2025 & 2033
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
  • 4.4. C1-Inhibitor Concentrates
    • 4.4.1. C1-Inhibitor Concentrates Market, 2021 - 2033 (USD Million)
  • 4.5. Bradykinin B2 Receptor Antagonist
    • 4.5.1. Bradykinin B2 Receptor Antagonist Market, 2021 - 2033 (USD Million)
  • 4.6. Kallikrein Inhibitor
    • 4.6.1. Kallikrein Inhibitor Market, 2021 - 2033 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Hereditary Angioedema Therapeutics Market: End Use Business Analysis

  • 5.1. End Use Market Share, 2025 & 2033
  • 5.2. End Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 5.4. Prophylaxis
    • 5.4.1. Prophylaxis Market, 2021 - 2033 (USD Million)
  • 5.5. On-demand
    • 5.5.1. On-demand Market, 2021 - 2033 (USD Million)

Chapter 6. Hereditary Angioedema Therapeutics Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2025 & 2033
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of administration, 2021 to 2033 (USD Million)
  • 6.4. Intravenous
    • 6.4.1. Intravenous Market, 2021 - 2033 (USD Million)
  • 6.5. Subcutaneous
    • 6.5.1. Subcutaneous Market, 2021 - 2033 (USD Million)
  • 6.6. Oral
    • 6.6.1. Oral Market, 2021 - 2033 (USD Million)

Chapter 7. Hereditary Angioedema Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Hereditary Angioedema Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. End Use Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. End Use Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. End Use Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. End Use Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. Uk Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. End Use Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. End Use Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. End Use Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. End Use Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. End Use Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. End Use Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. End Use Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. End Use Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. End Use Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. End Use Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. End Use Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. End Use Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. End Use Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. End Use Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Japan Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. End Use Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. China Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. End Use Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. End Use Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. End Use Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. End Use Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. BioCryst Pharmaceuticals, Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Treatment Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Ionis Pharmaceuticals
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Treatment Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. CSL
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Treatment Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Attune Pharmaceuticals
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Treatment Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Adverum Biotechnologies, Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Treatment Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. KalVista Pharmaceuticals, Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Treatment Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Takeda Pharmaceutical Company Limited
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Treatment Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Pharming
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Treatment Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Sanofi
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Treatment Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Pharvaris B.V.
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Treatment Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. Arrowhead Pharmaceuticals, Inc.
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Treatment Benchmarking
      • 8.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global hereditary angioedema therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 5 Global hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 6 Global hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 7 North America hereditary angioedema therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 9 North America hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 10 North America hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 11 U.S. hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 12 U.S. hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 13 U.S. hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 14 Canada hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 15 Canada hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 16 Canada hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 17 Mexico hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 18 Mexico hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Mexico hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 20 Europe hereditary angioedema therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 22 Europe hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 23 Europe hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 24 UK hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 25 UK hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 26 UK hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 27 Germany hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 28 Germany hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 29 Germany hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 30 France hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 31 France hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 32 France hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 33 Italy hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 34 Italy hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 35 Italy hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 36 Spain hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 37 Spain hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 38 Spain hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 39 Norway hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 40 Norway hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 41 Norway hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 42 Denmark hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 43 Denmark hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 44 Denmark hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 45 Sweden hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 46 Sweden hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 47 Sweden hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific hereditary angioedema therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD
  • Table 50 Asia Pacific hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 52 Japan hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 53 Japan hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 54 Japan hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 55 China hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 56 China hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 57 China hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 58 India hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 59 India hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 60 India hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 61 Australia hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 62 Australia hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 63 Australia hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 64 South Korea hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 65 South Korea hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 66 South Korea hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 67 Thailand hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 68 Thailand hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 69 Thailand hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 70 Latin America hereditary angioedema therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 72 Latin America hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 73 Latin America hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 74 Brazil hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 75 Brazil hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 76 Brazil hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 77 Argentina hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 78 Argentina hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 79 Argentina hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa hereditary angioedema therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 84 South Africa hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 85 South Africa hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 86 South Africa hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 90 UAE hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 91 UAE hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 92 UAE hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 93 Kuwait hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
  • Table 94 Kuwait hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
  • Table 95 Kuwait hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Hereditary angioedema therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Hereditary angioedema therapeutics market dynamics
  • Fig. 11 Hereditary angioedema therapeutics market: Porter's five forces analysis
  • Fig. 12 Hereditary angioedema therapeutics market: PESTLE analysis
  • Fig. 13 Treatment market, 2021 - 2033 (USD Million)
  • Fig. 14 C1-Inhibitor Concentrates market, 2021 - 2033 (USD Million)
  • Fig. 15 Bradykinin B2 Receptor Antagonist market, 2021 - 2033 (USD Million)
  • Fig. 16 Kallikrein Inhibitor market, 2021 - 2033 (USD Million)
  • Fig. 17 Others market, 2021 - 2033 (USD Million)
  • Fig. 18 End Use market, 2021 - 2033 (USD Million)
  • Fig. 19 Prophylaxis market, 2021 - 2033 (USD Million)
  • Fig. 20 On-demand market, 2021 - 2033 (USD Million)
  • Fig. 21 Route of administration market, 2021 - 2033 (USD Million)
  • Fig. 22 Intravenous market, 2021 - 2033 (USD Million)
  • Fig. 23 Subcutaneous market, 2021 - 2033 (USD Million)
  • Fig. 24 Oral market, 2021 - 2033 (USD Million)
  • Fig. 25 Hereditary angioedema therapeutics market revenue, by region
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 North America Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. country dynamics
  • Fig. 29 U.S. Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 30 Canada country dynamics
  • Fig. 31 Canada Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 32 Mexico country dynamics
  • Fig. 33 Mexico Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 34 Europe Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 35 UK country dynamics
  • Fig. 36 UK Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 37 Germany country dynamics
  • Fig. 38 Germany Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 39 France country dynamics
  • Fig. 40 France Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 41 Italy country dynamics
  • Fig. 42 Italy Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 43 Spain country dynamics
  • Fig. 44 Spain Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 45 Norway country dynamics
  • Fig. 46 Norway Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 47 Sweden country dynamics
  • Fig. 48 Sweden Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 49 Denmark country dynamics
  • Fig. 50 Denmark Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 51 Asia Pacific Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 52 Japan country dynamics
  • Fig. 53 Japan Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 54 China country dynamics
  • Fig. 55 China Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 56 India country dynamics
  • Fig. 57 India Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 58 Australia country dynamics
  • Fig. 59 Australia Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 60 South Korea country dynamics
  • Fig. 61 South Korea Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 62 Thailand country dynamics
  • Fig. 63 Thailand Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 64 Latin America Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 65 Brazil country dynamics
  • Fig. 66 Brazil Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 67 Argentina country dynamics
  • Fig. 68 Argentina Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 69 MEA Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 70 South Africa country dynamics
  • Fig. 71 South Africa Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 72 Saudi Arabia country dynamics
  • Fig. 73 Saudi Arabia Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 74 UAE country dynamics
  • Fig. 75 UAE Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 76 Kuwait country dynamics
  • Fig. 77 Kuwait Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 78 Company categorization
  • Fig. 79 Company market position analysis
  • Fig. 80 Strategic framework